Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDL NASDAQ:OKYO OTCMKTS:OPTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.03-3.7%$1.31$0.88▼$1.71$118.70M0.72351,527 shs288,383 shsOKYOOKYO Pharma$1.52-1.9%$1.61$1.42▼$3.35$61.64M0.0248,376 shs157,150 shsOPTIOptec International$0.00-66.7%$0.00$0.00▼$0.13$3KN/A430,258 shs8.26 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics-3.74%-7.21%-24.26%+0.98%-26.43%OKYOOKYO Pharma-1.94%-6.17%-6.17%-8.43%-34.76%OPTIOptec International-66.67%-25.00%-25.00%-75.00%-83.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.03-3.7%$1.31$0.88▼$1.71$118.70M0.72351,527 shs288,383 shsOKYOOKYO Pharma$1.52-1.9%$1.61$1.42▼$3.35$61.64M0.0248,376 shs157,150 shsOPTIOptec International$0.00-66.7%$0.00$0.00▼$0.13$3KN/A430,258 shs8.26 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics-3.74%-7.21%-24.26%+0.98%-26.43%OKYOOKYO Pharma-1.94%-6.17%-6.17%-8.43%-34.76%OPTIOptec International-66.67%-25.00%-25.00%-75.00%-83.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 2.33Hold$8.50725.24% UpsideOKYOOKYO Pharma 2.40Hold$6.33316.67% UpsideOPTIOptec International 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OPTI, CRDL, OKYO, and IGAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026OKYOOKYO Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026CRDLCardiol Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/AOKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/AOPTIOptec InternationalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)OKYOOKYO Pharma-$4.71MN/AN/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)OPTIOptec InternationalN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest OPTI, CRDL, OKYO, and IGAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/A3/30/2026Q4 2025CRDLCardiol Therapeutics-$0.09-$0.05+$0.04-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/AOPTIOptec InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol TherapeuticsN/A4.394.39OKYOOKYO PharmaN/A0.58N/AOPTIOptec InternationalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%OKYOOKYO Pharma2.97%OPTIOptec InternationalN/AInsider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%OKYOOKYO Pharma40.46%OPTIOptec International50.34%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableOKYOOKYO Pharma740.56 million24.15 millionNot OptionableOPTIOptec International111.65 millionN/ANot OptionableOPTI, CRDL, OKYO, and IGAS HeadlinesRecent News About These CompaniesOptimi Health Secures Ibogaine Supply and Commences Finished Drug Product DevelopmentJune 8, 2026 | globenewswire.comOptimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in AustraliaMay 29, 2026 | globenewswire.comDiamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)May 27, 2026 | globenewswire.comOptec International, Inc. (OPTI) - Yahoo FinanceJuly 13, 2025 | finance.yahoo.comOptec International Inc.May 23, 2025 | barrons.comOptec Technology Ltd.April 29, 2025 | optics.orgONew Optec CEO Updates ShareholdersJanuary 16, 2025 | globenewswire.comNew Optec CEO Updates ShareholdersJanuary 16, 2025 | prismmediawire.comPGlobal Optical Current Transformer Market Size Forecasted to Surpass USD 353.0 Million Valuation by 2033, Surging at 8.4% CAGRNovember 14, 2024 | fmiblog.comFSITC International Expands Fleet with New Vessel OrdersOctober 30, 2024 | markets.businessinsider.comAston University researcher develops new optical technique that could revolutionise medical diagnosticsOctober 25, 2024 | eurekalert.orgEbit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming TechnologyOctober 16, 2024 | standard-journal.comSOptical illusion psychology test: What you see first reveals if you are optimist or too cautious in lifeOctober 4, 2024 | timesofindia.indiatimes.comOpti Digital Welcomes Guillem Fiter as Chief Marketing OfficerSeptember 17, 2024 | exchangewire.comEOGP exhibiting exciting lineup of metrology systems at IMTS 2024September 5, 2024 | insights.globalspec.comIAndersen Global Enters Japan with the Collaborating Firm OptiAugust 30, 2024 | tmcnet.comThe Optical Women’s Association Announces Global Connection Event at Silmo ParisAugust 29, 2024 | invisionmag.comIOptical Communication and Networking Equipment Market to Reach $54.0 Billion, Globally, by 2032 at 8.7% CAGR: Allied Market ResearchAugust 20, 2024 | tmcnet.comEngineers bring efficient optical neural networks into focusAugust 14, 2024 | sciencedaily.comSOptical navigation tech could streamline planetary explorationAugust 7, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy Applied Optoelectronics Stock May Be Near a Turning PointBy Thomas Hughes | May 18, 2026Zscaler Stock Drops 30%: Why the Dip Is a Buy OpportunityBy Thomas Hughes | May 27, 2026Microsoft Build 2026 Is Really Just One Big AI Stress TestBy Chris Markoch | June 3, 2026Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for InvestorsBy Chris Markoch | June 2, 2026The SpaceX IPO Frenzy Is Creating 2 Very Different BetsBy Jeffrey Neal Johnson | May 27, 2026OPTI, CRDL, OKYO, and IGAS Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.03 -0.04 (-3.74%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.05 +0.02 (+2.33%) As of 06/12/2026 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.OKYO Pharma NASDAQ:OKYO$1.52 -0.03 (-1.94%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.53 +0.01 (+0.66%) As of 06/12/2026 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Optec International OTCMKTS:OPTI$0.0003 0.00 (-66.67%) As of 06/12/2026 03:52 PM EasternOptec International, Inc. engages in selling and marketing optimized fuel maximizer units in North America and internationally. It markets optimized fuel maximizer for passenger vehicles, intermediate/medium duty trucks, off-road equipment, generator systems, heavy duty diesel on-road vehicles, and transportation refrigeration units. The company was formerly known as Green Meadow Products, Inc. and changed its name to Optec International, Inc. in August 2017. Optec International, Inc. was founded in 2012 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
